相关实验视频
冠状动脉疾病中的七种静血基因多态:对66155例病例和91307例对照病例的元分析
Zheng Ye1, Eugene H C Liu, Julian P T Higgins
1Department of Public Health and Primary Care, University of Cambridge, Strangeways Site, Wort's Causeway, Cambridge CB1 8RN, UK.
Lancet (London, England)
|March 1, 2006
概括
某些V因子 (莱登) 和前列血的遗传变异可能适度增加冠状动脉疾病风险. 需要进一步的研究来证实这些关联,并探索对原血栓表型的治疗影响.
科学领域:
- 遗传学 是一个遗传学.
- 心血管医学 心血管医学
- 血栓形成的原因之一是血栓形成.
背景情况:
- 静血基因变异与静脉血栓症有关.
- 之前对这些冠状动脉疾病 (CAD) 变异的研究已经产生了相互矛盾的结果.
- 需要大规模的元分析来澄清这些关联.
研究的目的:
- 对七种常见的静血遗传变异与冠状动脉疾病风险之间的关联进行元分析.
- 调查这些协会中异质性的潜在来源.
- 提供关于这些变异在CAD病变发生中的作用的强有力的证据.
主要方法:
- 对191项涉及66155例CAD病例和91307例对照病例的研究进行了元分析.
- 检查的变体:因子V G1691A (莱登),因子VII G10976A,原血G20210A,PAI-1 [-675] 4G/5G,GPIa C807T,GPIbalpha T[-5]C,以及GPIIIa C1565T. 这两种变体都被研究了.
- 探索异质性和出版偏见.
主要成果:
- 因子V 1691A (莱登) 和新血红素20210A变体与增加的CAD风险 (RR分别为1.17和1.31) 有中度的关联.
- PAI-1 [-675] 4G变种显示了轻微的关联 (RR 1.06),有出版偏差的迹象.
- 第七因子,GPIa,GPIbalpha和GPIIIa变体与CAD没有显著的关联.
结论:
- 因子V 1691A和前列红素20210A变异可能与冠状动脉疾病风险中度相关.
- 这些变体增加了循环中血栓的产生.
- 进一步的研究是有必要的,以探索基因-基因/环境相互作用和潜在的治疗策略,以原血栓表型为目标.
相关概念视频
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...